Pub Date : 2025-03-26DOI: 10.26442/00403660.2025.02.203116
A I Parfenov, L K Indejkina, E A Sabelnikova, A V Leontiev, A A Makarova
This article addresses theoretical and clinical aspects of radiation-induced intestinal injuries, which complicate radiation therapy for malignant neoplasms of the abdominal and pelvic organs. Many clinical aspects of this issue remain unknown due to the lack of awareness among doctors and patients. Further study of radiation-induced intestinal injuries and the development of personalized approaches to their prevention and treatment represent a relevant direction in internal medicine.
{"title":"[Radiation-induced intestinal injury].","authors":"A I Parfenov, L K Indejkina, E A Sabelnikova, A V Leontiev, A A Makarova","doi":"10.26442/00403660.2025.02.203116","DOIUrl":"https://doi.org/10.26442/00403660.2025.02.203116","url":null,"abstract":"<p><p>This article addresses theoretical and clinical aspects of radiation-induced intestinal injuries, which complicate radiation therapy for malignant neoplasms of the abdominal and pelvic organs. Many clinical aspects of this issue remain unknown due to the lack of awareness among doctors and patients. Further study of radiation-induced intestinal injuries and the development of personalized approaches to their prevention and treatment represent a relevant direction in internal medicine.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 2","pages":"101-108"},"PeriodicalIF":0.3,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-26DOI: 10.26442/00403660.2025.02.203001
E A Sabelnikova, A V Kagramanova, O V Knyazev, S V Bykova, I N Ruchkina
The article discusses the main milestones in the development of enterology in the clinic of internal diseases. The review of the important stages of the study of diseases of the small and large intestine, its main achievements, discoveries resulting from the scientific and clinical work of outstanding Russian scientists. A deep understanding of pathological processes in diseases of the small intestine is discussed, diagnostic criteria and the possibility of identifying new nosological forms are considered.
{"title":"[Evolution of enterology as a science].","authors":"E A Sabelnikova, A V Kagramanova, O V Knyazev, S V Bykova, I N Ruchkina","doi":"10.26442/00403660.2025.02.203001","DOIUrl":"https://doi.org/10.26442/00403660.2025.02.203001","url":null,"abstract":"<p><p>The article discusses the main milestones in the development of enterology in the clinic of internal diseases. The review of the important stages of the study of diseases of the small and large intestine, its main achievements, discoveries resulting from the scientific and clinical work of outstanding Russian scientists. A deep understanding of pathological processes in diseases of the small intestine is discussed, diagnostic criteria and the possibility of identifying new nosological forms are considered.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 2","pages":"214-218"},"PeriodicalIF":0.3,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-21DOI: 10.26442/00403660.2025.01.203045
N B Lebedeva, I V Talibullin, P G Parfenov, O L Barbarash
Aim: Identification of a complex of clinical and anamnestic predictors of an unfavorable long-term prognosis in patients with heart failure with low left ventricular ejection fraction and an implanted cardioverter-defibrillator (ICD).
Materials and methods: In 260 patients with heart failure with low left ventricular ejection fraction and ICD included in the "Kuzbass Register of Patients with ICD", data were obtained on the status of alive/dead, causes of death and cardiovascular events during a 4-year follow-up period. The clinical-instrumental and socio-demographic parameters entered into the register before ICD implantation were used to compile a prognostic regression model.
Results: A total of 348 cardiovascular events (endpoints) were recorded, of which 54 were deaths. The main cause of death in 48 (88.9%) patients was acute decompensated heart failure. According to the multivariate regression analysis, the factors that increase the risk of an unfavorable long-term outcome included in the prognostic model were: the level of systolic pressure in the pulmonary artery, the thickness of the interventricular septum, social status, the presence of chronic obstructive pulmonary disease, the low ejection fraction of the left ventricle and the absence of a renin-blocker angiotensin-aldosterone system (model sensitivity - 70%, specificity - 75.9%, AUC=0.8).
Conclusion: The use of a predictive model in clinical practice will make it possible to personalize approaches to making a decision on the need for ICD implantation and further monitoring of patients in order to improve their survival.
{"title":"[Clinical and anamnestic predictors of poor long-term prognosis in patients with chronic heart failure and implanted cardioverter-defibrillator].","authors":"N B Lebedeva, I V Talibullin, P G Parfenov, O L Barbarash","doi":"10.26442/00403660.2025.01.203045","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203045","url":null,"abstract":"<p><strong>Aim: </strong>Identification of a complex of clinical and anamnestic predictors of an unfavorable long-term prognosis in patients with heart failure with low left ventricular ejection fraction and an implanted cardioverter-defibrillator (ICD).</p><p><strong>Materials and methods: </strong>In 260 patients with heart failure with low left ventricular ejection fraction and ICD included in the \"Kuzbass Register of Patients with ICD\", data were obtained on the status of alive/dead, causes of death and cardiovascular events during a 4-year follow-up period. The clinical-instrumental and socio-demographic parameters entered into the register before ICD implantation were used to compile a prognostic regression model.</p><p><strong>Results: </strong>A total of 348 cardiovascular events (endpoints) were recorded, of which 54 were deaths. The main cause of death in 48 (88.9%) patients was acute decompensated heart failure. According to the multivariate regression analysis, the factors that increase the risk of an unfavorable long-term outcome included in the prognostic model were: the level of systolic pressure in the pulmonary artery, the thickness of the interventricular septum, social status, the presence of chronic obstructive pulmonary disease, the low ejection fraction of the left ventricle and the absence of a renin-blocker angiotensin-aldosterone system (model sensitivity - 70%, specificity - 75.9%, AUC=0.8).</p><p><strong>Conclusion: </strong>The use of a predictive model in clinical practice will make it possible to personalize approaches to making a decision on the need for ICD implantation and further monitoring of patients in order to improve their survival.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"21-28"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-21DOI: 10.26442/00403660.2025.01.203101
A G Malyavin, S L Babak, A L Zaplatnikov, V А Bulgakova, M Y Garusova, M D Ilyukhina
Aim: To systematically analyze existing publications from available scientific databases (PubMed, Cochrane, eLibrary) for the period from 2018 to 2023 on the treatment of fever in children and adults with metamizole sodium (MS).
Materials and methods: A systematic review of scientific publications on the efficacy and safety of MS therapy for fever in adults and children compared to non-steroidal anti-inflammatory drugs was conducted. Six randomized clinical trials involving 884 patients (101 adults and 783 children) were included in the analysis.
Results: In all studies, MS has been demonstrated to be effective in reducing fever in both children and adults when used for short-term therapy. MS is superior to paracetamol, ibuprofen, acetylsalicylic acid and not inferior to nimesulide and propacetamol in terms of effectiveness in reducing body temperature between 1.5 and 6.0 hours after oral intake. It has been shown that treatment of fever with MS is a safer strategy compared to other non-steroidal anti-inflammatory drugs, as it has no clinically significant risks of gastric mucosal irritation, development of gastrointestinal bleeding and erosions. It has been established that therapeutic doses of MS do not lead to an increase in blood pressure, and in some cases contribute to hypotensive effect, especially in fever in adult comorbid patients with arterial hypertension.
Conclusion: MS is an effective treatment for fever in children and adults.
{"title":"[A systematic review on the safety and efficacy of metamizole sodium as a therapy for the treatment of fever in children and adults].","authors":"A G Malyavin, S L Babak, A L Zaplatnikov, V А Bulgakova, M Y Garusova, M D Ilyukhina","doi":"10.26442/00403660.2025.01.203101","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203101","url":null,"abstract":"<p><strong>Aim: </strong>To systematically analyze existing publications from available scientific databases (PubMed, Cochrane, eLibrary) for the period from 2018 to 2023 on the treatment of fever in children and adults with metamizole sodium (MS).</p><p><strong>Materials and methods: </strong>A systematic review of scientific publications on the efficacy and safety of MS therapy for fever in adults and children compared to non-steroidal anti-inflammatory drugs was conducted. Six randomized clinical trials involving 884 patients (101 adults and 783 children) were included in the analysis.</p><p><strong>Results: </strong>In all studies, MS has been demonstrated to be effective in reducing fever in both children and adults when used for short-term therapy. MS is superior to paracetamol, ibuprofen, acetylsalicylic acid and not inferior to nimesulide and propacetamol in terms of effectiveness in reducing body temperature between 1.5 and 6.0 hours after oral intake. It has been shown that treatment of fever with MS is a safer strategy compared to other non-steroidal anti-inflammatory drugs, as it has no clinically significant risks of gastric mucosal irritation, development of gastrointestinal bleeding and erosions. It has been established that therapeutic doses of MS do not lead to an increase in blood pressure, and in some cases contribute to hypotensive effect, especially in fever in adult comorbid patients with arterial hypertension.</p><p><strong>Conclusion: </strong>MS is an effective treatment for fever in children and adults.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"71-79"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-21DOI: 10.26442/00403660.2025.01.203146
O U Klimova, I K Golubovskaya, Y N Kuznetsov, M V Marchenko, A D Kulagin
Aim: To evaluate the hematological response within 4 weeks of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria and suboptimal response to long-term eculizumab therapy.
Materials and methods: The analysis included 8 patients, median age 32 years, with persistent anemia on long-term therapy with eculizumab. The hematological response was assessed when switching to oral monotherapy with iptacopan 200 mg twice daily for 4 weeks.
Results: After 4 weeks of iptacopan therapy, an increase in hemoglobin levels by more than 20 g/l was achieved in 7/8 (88%), and a complete response in 6/8 (75%) patients. The median increase in hemoglobin levels was 32.5 g/l from the initial 85.5 g/l (74-100) to 121.5 g/l (80-141); p=0.00013. Independence from red blood cell transfusions was achieved in 100% of cases. Achieving a hematological response to iptacopan therapy was accompanied by a decrease in the level of absolute reticulocyte count, bilirubin and lactate dehydrogenase, as well as a negative result of the anti-C3d direct antiglobulin test.
Conclusion: The oral complement factor B inhibitor iptacopan is an effective treatment option for paroxysmal nocturnal hemoglobinuria in patients with a suboptimal response to complement inhibitor C5 due to more effective control of extravascular C3-mediated hemolysis.
{"title":"[Efficacy of iptacopan monotherapy for suboptimal response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria].","authors":"O U Klimova, I K Golubovskaya, Y N Kuznetsov, M V Marchenko, A D Kulagin","doi":"10.26442/00403660.2025.01.203146","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203146","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the hematological response within 4 weeks of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria and suboptimal response to long-term eculizumab therapy.</p><p><strong>Materials and methods: </strong>The analysis included 8 patients, median age 32 years, with persistent anemia on long-term therapy with eculizumab. The hematological response was assessed when switching to oral monotherapy with iptacopan 200 mg twice daily for 4 weeks.</p><p><strong>Results: </strong>After 4 weeks of iptacopan therapy, an increase in hemoglobin levels by more than 20 g/l was achieved in 7/8 (88%), and a complete response in 6/8 (75%) patients. The median increase in hemoglobin levels was 32.5 g/l from the initial 85.5 g/l (74-100) to 121.5 g/l (80-141); <i>p</i>=0.00013. Independence from red blood cell transfusions was achieved in 100% of cases. Achieving a hematological response to iptacopan therapy was accompanied by a decrease in the level of absolute reticulocyte count, bilirubin and lactate dehydrogenase, as well as a negative result of the anti-C3d direct antiglobulin test.</p><p><strong>Conclusion: </strong>The oral complement factor B inhibitor iptacopan is an effective treatment option for paroxysmal nocturnal hemoglobinuria in patients with a suboptimal response to complement inhibitor C5 due to more effective control of extravascular C3-mediated hemolysis.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"46-53"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-21DOI: 10.26442/00403660.2025.01.203028
G O Isaev, O I Trushina, M A Isaikina, A A Bestavashvili, M V Yurazh, P Y Kopylov, M H Mnatsakanyan, V V Fomin
Aim: To evaluate the effect of inflammatory bowel disease (IBD) on the risk of atherosclerosis in patients without known cardiovascular disease.
Materials and methods: The study included 115 patients divided into three groups: 37 patients with Crohn's disease (CD), 44 with ulcerative colitis (UC), and 34 in the control group without known IBD and other risk factors. Doppler ultrasound of the brachiocephalic arteries and sphygmometry were used for diagnosis. The main indicators were the thickness of the intima-media complex (TIMC) and vascular stiffness, measured by the cardio-ankle vascular index (CAVI) and the ankle-brachial pressure index (ABI).
Results: IBD patients showed an increase in TIMC compared to controls. TIMC of the common carotid arteries on the right: in patients with CD - 0.07 cm (p=0.001), with UC - 0.08 cm (p=0.019), in the control group - 0.06 cm. TIMC of the common carotid arteries on the left: in patients with CD - 0.07 cm (p=0.001), with UC - 0.07 cm (p=0.012), in the control group - 0.06 cm. The sphygmometry indicators (CAVI and ABI) did not differ significantly between the groups. The mean CAVI on the right was 6.8±0.98 for the CD group, 6.6±0.79 for the UC group, and 6.82±0.76 for the control group (p=0.692).
Conclusion: IBD can contribute to the thickening of the vascular walls, thus increasing the risk of atherosclerosis, as shown by TIMC. Vascular stiffness indicators (CAVI, ABI) did not differ significantly between the groups.
目的:评价炎症性肠病(IBD)对无已知心血管疾病患者动脉粥样硬化风险的影响。材料和方法:研究纳入115例患者,分为3组:克罗恩病(CD)患者37例,溃疡性结肠炎(UC)患者44例,对照组34例,无已知IBD及其他危险因素。采用多普勒头臂动脉超声和血压计进行诊断。主要指标为内膜-中膜复合体厚度(TIMC)和血管刚度,通过心-踝血管指数(CAVI)和踝-肱压力指数(ABI)测量。结果:与对照组相比,IBD患者TIMC升高。右侧颈总动脉TIMC: CD组- 0.07 cm (p=0.001), UC组- 0.08 cm (p=0.019),对照组- 0.06 cm。左侧颈总动脉TIMC: CD组- 0.07 cm (p=0.001), UC组- 0.07 cm (p=0.012),对照组- 0.06 cm。两组间血压计指标(CAVI和ABI)无显著差异。右侧CAVI平均值CD组为6.8±0.98,UC组为6.6±0.79,对照组为6.82±0.76 (p=0.692)。结论:TIMC显示IBD可导致血管壁增厚,从而增加动脉粥样硬化的风险。血管硬度指标(CAVI, ABI)组间无显著差异。
{"title":"[The effect of inflammatory bowel diseases on the risk of atherosclerosis: assessment according to ultrasound imaging and sphygmometry].","authors":"G O Isaev, O I Trushina, M A Isaikina, A A Bestavashvili, M V Yurazh, P Y Kopylov, M H Mnatsakanyan, V V Fomin","doi":"10.26442/00403660.2025.01.203028","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203028","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the effect of inflammatory bowel disease (IBD) on the risk of atherosclerosis in patients without known cardiovascular disease.</p><p><strong>Materials and methods: </strong>The study included 115 patients divided into three groups: 37 patients with Crohn's disease (CD), 44 with ulcerative colitis (UC), and 34 in the control group without known IBD and other risk factors. Doppler ultrasound of the brachiocephalic arteries and sphygmometry were used for diagnosis. The main indicators were the thickness of the intima-media complex (TIMC) and vascular stiffness, measured by the cardio-ankle vascular index (CAVI) and the ankle-brachial pressure index (ABI).</p><p><strong>Results: </strong>IBD patients showed an increase in TIMC compared to controls. TIMC of the common carotid arteries on the right: in patients with CD - 0.07 cm (<i>p</i>=0.001), with UC - 0.08 cm (<i>p</i>=0.019), in the control group - 0.06 cm. TIMC of the common carotid arteries on the left: in patients with CD - 0.07 cm (<i>p</i>=0.001), with UC - 0.07 cm (<i>p</i>=0.012), in the control group - 0.06 cm. The sphygmometry indicators (CAVI and ABI) did not differ significantly between the groups. The mean CAVI on the right was 6.8±0.98 for the CD group, 6.6±0.79 for the UC group, and 6.82±0.76 for the control group (<i>p</i>=0.692).</p><p><strong>Conclusion: </strong>IBD can contribute to the thickening of the vascular walls, thus increasing the risk of atherosclerosis, as shown by TIMC. Vascular stiffness indicators (CAVI, ABI) did not differ significantly between the groups.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"29-34"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-21DOI: 10.26442/00403660.2025.01.203030
S Y Kashtanova, E М Rimskaya, A N Meshkov, N А Mironova, I K Dzhumaniiazova, E A Zelenova, V V Daniel', M V Ivanov, D A Kashtanova, V S Yudin, A A Keskinov, S I Mitrofanov, A I Akinshina, Y N Vanyushina, S А Kraevoy, S M Yudin, S P Golitsyn
We present a clinical case of familial LMNA-associated cardiomyopathy, confirmed by whole genome sequencing. The typical for lamin-associated cardiomyopathy indicates pathogenic nature of the mutation in the first exon of LMNA gene, previously considered a mutation of unknown clinical significance. The presented clinical case demonstrates a radical change in patient treatment strategies in the context of the widespread introduction of molecular genetic research methods into practice.
{"title":"[New pathogenic mutation in LMNA gene: Clinical case of familial cardiomyopathy].","authors":"S Y Kashtanova, E М Rimskaya, A N Meshkov, N А Mironova, I K Dzhumaniiazova, E A Zelenova, V V Daniel', M V Ivanov, D A Kashtanova, V S Yudin, A A Keskinov, S I Mitrofanov, A I Akinshina, Y N Vanyushina, S А Kraevoy, S M Yudin, S P Golitsyn","doi":"10.26442/00403660.2025.01.203030","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203030","url":null,"abstract":"<p><p>We present a clinical case of familial <i>LMNA</i>-associated cardiomyopathy, confirmed by whole genome sequencing. The typical for lamin-associated cardiomyopathy indicates pathogenic nature of the mutation in the first exon of <i>LMNA</i> gene, previously considered a mutation of unknown clinical significance. The presented clinical case demonstrates a radical change in patient treatment strategies in the context of the widespread introduction of molecular genetic research methods into practice.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"65-70"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-21DOI: 10.26442/00403660.2025.01.203145
L I Alekseeva, N G Kashevarova, E A Taskina, E A Strebkova, T A Korotkova, E P Sharapova, N M Savushkina, A M Lila, N A Shostak, I I Nesterovich, V A Dedkova, V B Vasilyuk, N V Egorova, M A Leontyeva, S P Yakupova, I B Vinogradova, V N Sorotskaya, L I Shirokova, A V Rudakova
Introduction: Current strategies for treating osteoarthritis (OA) are based on a multimodal approach that includes pharmacological and non-pharmacological methods. Undenatured chicken collagen type II (NK2) is considered safe and effective for maintaining joint health and can be used alone and combined with drugs for OA treatment.
Aim: To further evaluate the efficacy of the combination of Artneo containing NK2 in patients with stage III knee OA compared with placebo in a multicenter, prospective, double-blind, placebo-controlled, randomized trial.
Materials and methods: The study included 212 patients from 12 centers in the Russian Federation, of whom 50 had radiological stage III knee OA: 41 (82.0%) females and 9 (18.0%) males aged 44 to 75. Using the interactive web response system (IWRS), the study population was randomized into two groups: Group 1 (Artneo group) included 28 patients receiving the drug 1 capsule once a day for 180 days, Group 2 (placebo group) included 22 patients receiving placebo with drug-matched presentation and the same regimen as in Group 1. The effectiveness of therapy was assessed by the change of pain using the Visual Analog Scale, the WOMAC index, KOOS, the EQ-5D quality of life questionnaire, and the need for non-steroidal anti-inflammatory drugs. All patients had a complete blood count, urinalysis, blood chemistry, and ultrasonic examination of the target knee joint.
Results: A prospective, double-blind, placebo-controlled, randomized trial demonstrated that Artneo containing NK2 was significantly superior to placebo in all studied parameters, improved all clinical manifestations of OA: reduced pain and stiffness, improved joint function and quality of life, and had a good safety profile.
Conclusion: Artneo showed high efficacy and safety in the general population of patients, including those with stage III knee OA.
{"title":"[Experience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial].","authors":"L I Alekseeva, N G Kashevarova, E A Taskina, E A Strebkova, T A Korotkova, E P Sharapova, N M Savushkina, A M Lila, N A Shostak, I I Nesterovich, V A Dedkova, V B Vasilyuk, N V Egorova, M A Leontyeva, S P Yakupova, I B Vinogradova, V N Sorotskaya, L I Shirokova, A V Rudakova","doi":"10.26442/00403660.2025.01.203145","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203145","url":null,"abstract":"<p><strong>Introduction: </strong>Current strategies for treating osteoarthritis (OA) are based on a multimodal approach that includes pharmacological and non-pharmacological methods. Undenatured chicken collagen type II (NK2) is considered safe and effective for maintaining joint health and can be used alone and combined with drugs for OA treatment.</p><p><strong>Aim: </strong>To further evaluate the efficacy of the combination of Artneo containing NK2 in patients with stage III knee OA compared with placebo in a multicenter, prospective, double-blind, placebo-controlled, randomized trial.</p><p><strong>Materials and methods: </strong>The study included 212 patients from 12 centers in the Russian Federation, of whom 50 had radiological stage III knee OA: 41 (82.0%) females and 9 (18.0%) males aged 44 to 75. Using the interactive web response system (IWRS), the study population was randomized into two groups: Group 1 (Artneo group) included 28 patients receiving the drug 1 capsule once a day for 180 days, Group 2 (placebo group) included 22 patients receiving placebo with drug-matched presentation and the same regimen as in Group 1. The effectiveness of therapy was assessed by the change of pain using the Visual Analog Scale, the WOMAC index, KOOS, the EQ-5D quality of life questionnaire, and the need for non-steroidal anti-inflammatory drugs. All patients had a complete blood count, urinalysis, blood chemistry, and ultrasonic examination of the target knee joint.</p><p><strong>Results: </strong>A prospective, double-blind, placebo-controlled, randomized trial demonstrated that Artneo containing NK2 was significantly superior to placebo in all studied parameters, improved all clinical manifestations of OA: reduced pain and stiffness, improved joint function and quality of life, and had a good safety profile.</p><p><strong>Conclusion: </strong>Artneo showed high efficacy and safety in the general population of patients, including those with stage III knee OA.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"54-64"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-21DOI: 10.26442/00403660.2025.01.203029
M S Novikova, L O Minushkina, O N Kotenko, D A Zateyshchikov, O I Boeva, S S Allazova, E M Shilov, O M Koteshkova, M B Antsiferov
Aim: To compare risk factors for new-onset diabetes after transplantation (NODAT) among renal transplant recipients (RTRs) from 1989 to 2018 in the City Clinical Hospital №52, with a systematic analysis of published studies on this topic.
Materials and methods: In a 30-year (1989-2018) retrospective study, we found statistically significant differences in age, gender, polycystic kidney disease, cadaveric kidney, cyclosporine, i-mTOR, and steroids between two groups of recipients with and without NODAT. Patients with NODAT were older, more male, more likely to have polycystic kidney disease and deceased donor kidneys, and more likely to be treated with cyclosporine, i-mTOR, and steroids (p<0.05). We conducted a meta-analysis to evaluate the impact of these indicators on the development of NODAT. MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials were searched for eligible case-control studies of risk factors for NODAT in RTRs published between 1990 and 2019. Meta-analysis of proportions was performed using the Freeman-Tukey transformation to calculate weighted summary proportions from a fixed and random effects model.
Results: A total of 13 case-control studies were included in the meta-analysis. Of the total 849 studies found, 13 were included in the systematic review and meta-analysis, including ours, with a total of n=6797 RTRs, of which n=1305 patients with NODAT and n=5492 without NODAT. A wide range of data was recorded for the analysis of the incidence of NODAT (6.5-50.7%), with an average of 17.9% (fixed model) or 24.3% (random model). The proportion of NODAT recorded in the Russian registry of the City Clinical Hospital №52 was lower (11.5%), however, the data in the analyzed studies were highly heterogeneous: I2=98.14%, 95% CI: from 97.61 to 98.55, p<0.0001, Begg's test (p=0.05) and Egger's test (p=0.01) do not exclude the presence of publication bias in this case. Data on NODAT risk factors were less heterogeneous. This meta-analysis showed that age, polycystic kidney disease, i-mTOR and steroid therapy were associated with NODAT, whereas gender, calcineurin inhibitor use, and cadaveric kidney were not. There was no evidence of selection bias in any of the cases.
Conclusion: Risk factors for NODAT in kidney transplant recipients include older age, polycystic kidney disease, i-mTOR and steroid therapy, which initiate a state of insulin resistance. To reduce the risk of NODAT, the possibility of modifying immunosuppression regimens and the use of drugs that reduce insulin resistance and have a nephroprotective effect in RTRs should be considered. Therefore, randomized studies are needed to evaluate SGLT2 inhibitor in RTRs.
{"title":"[Risk factors for new-onset diabetes after transplantation in kidney transplant recipients: own data and meta-analysis].","authors":"M S Novikova, L O Minushkina, O N Kotenko, D A Zateyshchikov, O I Boeva, S S Allazova, E M Shilov, O M Koteshkova, M B Antsiferov","doi":"10.26442/00403660.2025.01.203029","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203029","url":null,"abstract":"<p><strong>Aim: </strong>To compare risk factors for new-onset diabetes after transplantation (NODAT) among renal transplant recipients (RTRs) from 1989 to 2018 in the City Clinical Hospital №52, with a systematic analysis of published studies on this topic.</p><p><strong>Materials and methods: </strong>In a 30-year (1989-2018) retrospective study, we found statistically significant differences in age, gender, polycystic kidney disease, cadaveric kidney, cyclosporine, i-mTOR, and steroids between two groups of recipients with and without NODAT. Patients with NODAT were older, more male, more likely to have polycystic kidney disease and deceased donor kidneys, and more likely to be treated with cyclosporine, i-mTOR, and steroids (<i>p</i><0.05). We conducted a meta-analysis to evaluate the impact of these indicators on the development of NODAT. MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials were searched for eligible case-control studies of risk factors for NODAT in RTRs published between 1990 and 2019. Meta-analysis of proportions was performed using the Freeman-Tukey transformation to calculate weighted summary proportions from a fixed and random effects model.</p><p><strong>Results: </strong>A total of 13 case-control studies were included in the meta-analysis. Of the total 849 studies found, 13 were included in the systematic review and meta-analysis, including ours, with a total of <i>n</i>=6797 RTRs, of which <i>n</i>=1305 patients with NODAT and <i>n</i>=5492 without NODAT. A wide range of data was recorded for the analysis of the incidence of NODAT (6.5-50.7%), with an average of 17.9% (fixed model) or 24.3% (random model). The proportion of NODAT recorded in the Russian registry of the City Clinical Hospital №52 was lower (11.5%), however, the data in the analyzed studies were highly heterogeneous: <i>I</i><sup>2</sup>=98.14%, 95% CI: from 97.61 to 98.55, <i>p</i><0.0001, Begg's test (<i>p</i>=0.05) and Egger's test (<i>p</i>=0.01) do not exclude the presence of publication bias in this case. Data on NODAT risk factors were less heterogeneous. This meta-analysis showed that age, polycystic kidney disease, i-mTOR and steroid therapy were associated with NODAT, whereas gender, calcineurin inhibitor use, and cadaveric kidney were not. There was no evidence of selection bias in any of the cases.</p><p><strong>Conclusion: </strong>Risk factors for NODAT in kidney transplant recipients include older age, polycystic kidney disease, i-mTOR and steroid therapy, which initiate a state of insulin resistance. To reduce the risk of NODAT, the possibility of modifying immunosuppression regimens and the use of drugs that reduce insulin resistance and have a nephroprotective effect in RTRs should be considered. Therefore, randomized studies are needed to evaluate SGLT2 inhibitor in RTRs.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"35-45"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-21DOI: 10.26442/00403660.2025.01.203139
E V Surkova, I V Glinkina, O Y Gurova, D V Mamleeva, G R Galstyan
The article describes the history of the formation of therapeutic education as one of the most essential components of the treatment of chronic diseases, in particular diabetes. The varieties and methods of programs for patients existing in the Russian Federation are considered in detail.
{"title":"[History of patient education for chronic diseases (with diabetes mellitus as an example): from an idea to the branch of modern medicine].","authors":"E V Surkova, I V Glinkina, O Y Gurova, D V Mamleeva, G R Galstyan","doi":"10.26442/00403660.2025.01.203139","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203139","url":null,"abstract":"<p><p>The article describes the history of the formation of therapeutic education as one of the most essential components of the treatment of chronic diseases, in particular diabetes. The varieties and methods of programs for patients existing in the Russian Federation are considered in detail.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"86-93"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}